Tumor necrosis factor-α antagonists: Side effects and their management.

Simple item page
dc.contributor.authorDogra, Sunil
dc.contributor.authorKhullar, Geeti
dc.date.accessioned2013-07-25T09:51:27Z
dc.date.available2013-07-25T09:51:27Z
dc.date.issued2013-07
dc.description.abstractAs elevated levels of tumor necrosis factor-alpha (TNF-α) are associated with disease severity in psoriasis and psoriatic arthritis, TNF-α antagonists are being used to treat moderate to severe disease in patients who have contraindications, fail to respond or develop side effects to conventional systemic therapies. It is of utmost importance to be well versed with the possible adverse effects and contraindications of TNF-α antagonists so that they can be used effectively and safely. Many of their adverse effects have been well studied in patients of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) and may not be completely applicable in psoriasis. This is because patients with RA and IBD are on multiple immunosuppressants while those with psoriasis are mostly receiving single systemic therapy and often have comorbidities that distinguish them from those with RA or IBD. Also, some of the side effects are still controversial and debated. Long-term prospective randomized controlled studies are needed to better understand the associated risk in patients of psoriasis. Baseline screening and periodic monitoring during treatment can reduce and help in early identification and appropriate management of the adverse outcomes. This article reviews the side effects known to be associated with TNF-α antagonists, their pathomechanisms and management guidelines. Some of the common side effects include infusion and injection site reactions, infections particularly reactivation of tuberculosis, autoantibody formation and drug induced lupus erythematosus, liver function abnormalities, hematological, and solid organ malignancies.en_US
dc.identifier.citationDogra Sunil, Khullar Geeti. Tumor necrosis factor-α antagonists: Side effects and their management. Indian Journal of Dermatology, Venereology and Leprology. 2013 July; 79 Suppl(): S35-46.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/147530
dc.language.isoenen_US
dc.source.urihttps://www.ijdvl.com/article.asp?issn=0378-6323;year=2013;volume=79;issue=7;spage=35;epage=46;aulast=Dograen_US
dc.subjectManagementen_US
dc.subjectside effectsen_US
dc.subjecttumor necrosis factor-α antagonistsen_US
dc.subject.meshAbnormalities, Drug-Induced --etiology
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal --adverse effects
dc.subject.meshAntibodies, Monoclonal --adverse effects
dc.subject.meshAntibodies, Monoclonal, Humanized --adverse effects
dc.subject.meshDrug Hypersensitivity --etiology
dc.subject.meshDrug Hypersensitivity --therapy
dc.subject.meshHumans
dc.subject.meshImmunoglobulin G --adverse effects
dc.subject.meshInjections --adverse effects
dc.subject.meshLatent Tuberculosis --chemically induced
dc.subject.meshLatent Tuberculosis --drug therapy
dc.subject.meshLiver --drug effects
dc.subject.meshLiver --physiopathology
dc.subject.meshNeoplasms --chemically induced
dc.subject.meshNervous System Diseases --chemically induced
dc.subject.meshPsoriasis --chemically induced
dc.subject.meshReceptors, Tumor Necrosis Factor
dc.subject.meshThrombocytopenia --chemically induced
dc.subject.meshThromboembolism --chemically induced
dc.subject.meshTumor Necrosis Factor-alpha --antagonists & inhibitors
dc.titleTumor necrosis factor-α antagonists: Side effects and their management.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijdvl2013v79n7ps35.pdf
Size:
474.8 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Dermatology, Venereology and Leprology